← United States · All US Insider Profiles
US INSIDER PROFILE · NON-SCORING RESEARCH
Mosseri Marlio Charles
10% Owner
Identity: SEC reporting-owner CIK · Reporting-owner CIK: 0001806384
Purchase history
- Companies traded
- 1
- Purchases · 12M
- 2
- Purchases · 24M
- 10
- Average purchase
- $435.0K
- Median purchase
- $241.0K
- Gross purchase value
- $4.3M
Companies: Nuvectis Pharma, Inc.
10 SEC accession(s) · 0 joint-owner event(s). Values are reported Form 4 transaction values in USD.
Qualifying purchase disclosures
| Published | Company | Ticker | Role | Reported value | SEC source |
|---|---|---|---|---|---|
| 2026-07-01 | Nuvectis Pharma, Inc. | NVCT | 10% Owner | $916.0K | Open filing |
| 2025-10-29 | Nuvectis Pharma, Inc. | NVCT | 10% Owner | $957.1K | Open filing |
| 2025-06-24 | Nuvectis Pharma, Inc. | NVCT | 10% Owner | $44.8K | Open filing |
| 2025-06-20 | Nuvectis Pharma, Inc. | NVCT | 10% Owner | $269.5K | Open filing |
| 2025-05-13 | Nuvectis Pharma, Inc. | NVCT | 10% Owner | $171.7K | Open filing |
| 2025-05-12 | Nuvectis Pharma, Inc. | NVCT | 10% Owner | $247.3K | Open filing |
| 2025-05-09 | Nuvectis Pharma, Inc. | NVCT | 10% Owner | $234.8K | Open filing |
| 2025-02-11 | Nuvectis Pharma, Inc. | NVCT | 10% Owner | $1.2M | Open filing |
| 2024-12-16 | Nuvectis Pharma, Inc. | NVCT | 10% Owner | $79.9K | Open filing |
| 2024-12-16 | Nuvectis Pharma, Inc. | NVCT | 10% Owner | $228.9K | Open filing |
Post-purchase outcomes
Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.
No completed point-in-time price outcome is available yet.
Research patterns
- First purchase in 12M
- 0/9
- Large purchase ≥ $100k
- 8/10
- Cluster buying · 15D
- 1/10
- Buying the dip
- 0/—
Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.
Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.